Business Context and Reporting Period
This Form 8-K Current Report was filed by Pyxis Oncology, Inc. on September 03, 2026. The filing primarily addresses significant corporate governance changes, including the appointment of a permanent Chief Executive Officer and Chairman of the Board, the establishment of a Lead Independent Director role, and the resignation of a board member.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation arrangements and board composition changes.
Material Changes
- Executive Appointment: Thomas Civik was appointed as permanent Chief Executive Officer and Chairman of the Board, effective September 4, 2026, succeeding his role as Interim CEO.
- Board Restructuring: The roles of Chairman and CEO were combined. John Flavin was appointed as the new Lead Independent Director and Chair of the Compensation Committee.
- Board Resignation: Dr. Santhosh Palani resigned from the Board and all committees effective September 4, 2026, reducing the Board size from eight to seven members.
- Compensation Arrangements: Mr. Civik's employment agreement was amended to include a $710,000 annual base salary, a 60% target bonus, a $100,000 one-time sign-on bonus, and a new stock option grant for 2,503,050 shares.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of market risks. The primary contingency noted relates to Mr. Civik's compensation, specifically the repayment of the $100,000 sign-on bonus if his employment is terminated for Cause or he resigns without Good Reason within six months of the appointment. Additionally, the filing notes that Dr. Palani's resignation was due to increased time commitments and not the result of any dispute with the Company.
Investor Verification Checklist
- Verify the terms of the First Amendment to the Interim CEO Employment Agreement, specifically the vesting schedule for the 2,503,050 new stock options.
- Confirm the composition of the Board of Directors following the resignation of Dr. Palani and the appointment of Mr. Civik as Chairman.
- Review the upcoming Form 10-Q for the quarter ending September 30, 2026, where the full text of the employment amendment will be filed as an exhibit.
- Assess the impact of combining the Chairman and CEO roles on the company's independent oversight structure, noting the creation of the Lead Independent Director position.